Download This PDF File

Total Page:16

File Type:pdf, Size:1020Kb

Download This PDF File 114 AMJ March, 2015 Effect of Centella asiatica Leaves on Gastric Ulcer in Rats Ester Mariska1, Trully D. Sitorus2, Januarsih A. Rachman3 1Faculty of Medicine, Universitas Padjadjaran, 2Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, 3Department of Biology Cell, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia Abstract Background: Gastric ulcer is disruption of gastric mucosal integrity due to lack of smaller defensive factors (e.g. mucus levels) than gastric aggressive factors. Centella asiatica is a traditional medicine that contains Centella asiatica leaves for preventing gastric mucus level reduction of aspirin-induced gastric ulcer model triterpenoidsin rats and compared and flavonoids. it to misoprostol. The objective of this study was to analyze the effect of ethanol extract of Methods: aspirin 450mg/kg, An experimental group III laboratory (tested group) study usingreceived 24 ratsCentella that wereasiatica divided 400 mg/kginto 4 groups. and aspirin Group 450 I (negative mg/kg, control) received carboxymethy cellulose (CMC) solution, group II (positive control) received CMC and group IV (compared group) received misoprostol 72μg/kg and aspirin 450mg/kg for three days. Then theResults: rats were laparatomied and their gastric mucus levels were measured. The results were statistically analyzed by Independent T-test. The mean levels of gastric mucus of group I, II, III, IV, respectively were 0.112; 0.035; 0.537; 0.455 opticalgroup and densities compared per group.gram of tissue. The statistical test suggested a significant difference between the positiveConclusions: control Centella group asiaticaand tested leaves group. can preventMoreover gastric there mucus is no significantlevel reduction difference of aspirin-induced between the gastrictested ulcerKeywords: model Centella in rats and asiatica has similar, gastric effect mucus, in gastricgastric mucusulcer, misoprostol level with misoprostol. Introduction 2 Gastric ulcer is disruption of gastric Traditional medicines The percentage have been of Indonesian used for treatment from generation to generation based mucosal integrityand arises from the 3 smaller level of defensive factors (e.g. on experiences. Traditional medicine mucus levels) than gastric aggressive ispopulation medicine who derived use traditionalfrom plants, medicine animals, is about 22.26% in 2008. One of these traditional medicines is Centella and antiplatelet over a long period of time. minerals,asiatica. or a mixture of these materials. factors.1This condition can be triggered Centella asiatica is a short-stemmed by the use of aspirin as anti-inflammatory for leprosy, syphilis, fever, and plays a role andPatients vomiting. with The gastric pain ulcers arises often after complain eating. ofThis epigastric situation pain, led burning to decreased sensation, patient’s nausea, creeping plant that have been used as a cure productivity. Therefore, the patients require in wound healing, increasing work capacity medicine, such as misoprostol, or traditional of neurotransmitters in the brain,Centella and asiatica treatmentsmedicine. Thewhich mechanism may include of action modern of revitalizing body tissues. It grows in tropical misoprostol as a prostaglandin analogue and subtropical regions, e.g. Indonesia. is stimulating the secretion of mucus and and small has fruits. branched The height tap root, of Centella green leaves asiatica in ais fan-shaped 10-50 cm.4 or kidney-shaped, round flowers, 1 the effect of Centella asiatica against gastric bicarbonate, reducing mucosal cell turnover, The objective of this study was to analyze andCorrespondence: increasing mucosalEster Mariska, blood Faculty flow. of Medicine, Universitas Padjadjaran, Jalan Raya Bandung-Sumedang Km.21, Jatinangor, Sumedang, Indonesia, Phone: +62 813 8684 1321 Email: [email protected] Althea Medical Journal. 2015;2(1) Ester Mariska, Trully D. Sitorus, Januarsih A. Rachman: Effect of Centella asiatica Leaves on Gastric Ulcer in Rats 115 Figure 1 Procedures of The Experiment ulcers and to compare the effect of Centella asiatica 24 male wistar strain rats with inclusion Methodswith misoprostol. criterias as follows: 8-12 weeks old, 150-200 grams weight, active movement, clean hair, no wound on the body, and normal stools. The exclusion criteria are weight lost more than AnAlthea experimental Medical Journal. study 2015;2(1) was carried out, using 10% of the initial body weight during the 116 AMJ March, 2015 adaptation and sickness after the adaptation. of Sekolah Ilmu Teknologi Hayati Institut repair, as well as stimulating mucosal damage. The rats were obtained from the Laboratory Theif NSAIDs NSAIDs are arein acidicweak environment.acids. The NSAIDsIn that will remain as non-ionized lipophilic form Teknologiof Dr.Hasan BandungSadikin General and were Hospital adapted Bandung for seven days in the Pharmacological Laboratory condition,in the cell. NSAIDsIf the drugs will crossare trapped through inside the lipid the environment.5 The leaves of Centella asiatica membranes of epithelial cells and be1The trapped dose to prevent or minimize the stress in a new cell, then the cell will be damaged. were obtained from Kebun Percobaan Manoko, of aspirin was 450 mg/kg body weight. The Kecamatan Lembang, West Bandung, West dosesand humans.used in this7 study were the results from Java and extracted in Balai Penelitian Tanaman conversion using table experimental animals Rempah dan Obat, Bogor, West Java. The fresh ml CMC solution andCentella given orallyasiatica to theextracts, rats.8 leavesfrom dirt were or harvested foreign material at the age and of reduce 3-6 months. from aspirin, and misoprostol were dissolved in 5 The leaves were sorted and washed to clean celluloseThe rats (CMC) were dividedsolution, into group 4 groups. II (positive Group microbial. Then, the leaves were pulverized. Icontrol) (negative received control) CMC received and aspirin carboxymethy 450mg/ Next, the sample was mixed with ethanol kg, group III (tested group) received Centella (70%) with a ratio of 1:5 in shaking water asiatica 400 mg/kg and aspirin 450 mg/ bathconcentrated for 3 hours in a and rotatory allowed evaporator to steady at for 500C 16 kg, group IV (compared group) received hours. The sample was filtered by filter paper, for 6 hours, and dried with a freezer dryer for misoprostolto determine 72μg/kgthe normal and gastric aspirin mucus 450mg/kg level in 2 days. Twenty kg of wet Centella asiatica plant during three days. The function of group I was (all parts) became 836.5 grams of dried leaves6 and became 96 grams of dried extract. The rats. After 3 days, all the rats were scarified by dose of extract was 400 mg/kg body weight. ketamine and were laparatomied. Their gastric Misoprostol was used as a comparative drug mucususing thelevels Green were AP, collected Lander JE,and Turner, measured DH andanalogue obtained has from mechanisms PT Novell Pharmaceuticalof action for by spectrophotometer (wavelength 605 nm) Laboratories.stimulating theMisoprostol secretion as ofa prostaglandinmucus and (1981)Unit Penelitian method. Kesehatan The measurement Rumah Sakit of gastricUmum 1 The dose mucusPusat Dr. levels Hasan was Sadikin done Bandung.in the Laboratory The results of bicarbonate, reducing mucosal cell turnover, and increasing mucosal blood flow. of misoprostol was 72 μg/kg body weight. In were analyzed using Independent T-test. The this study, Aspirin was used to create a gastric test in this study used Confidence interval (CI) ulcer condition in the rats and was obtained 95% (α= 5%). The measurement from(NSAIDs). PT Bayer Mechanism Indonesia. of Aspirin action belongsof NSAIDs to a The procedures were based9 on the research class of Nonsteroidal Anti-inflammatory Drugs of M. Sancar et. al. (2009). 10 (Figure mechanism can harm mucosal defense and of1) mucus levels were based on the Green AP, is to inhibit synthesis of prostaglandin. This Lander JE, TurnerDH (1981) method. Table 1 Gastric Mucus Levels of the Gastric Ulcer Induced Rats Gastric Mucus Level (optical density units per gram of tissue) Group Group I Group II Group III Group IV 1 0.186 0.047 0.585 0.528 2 0.050 0.028 0.720 0.370 3 0.070 0.061 0.652 0.573 4 0.140 0.015 0.361 5 0.134 0.011 0.411 0.556 0.339 6 0.048 0.513 0.342 Mean(SD) 0.112(0.051) 0.035(0.020) 0.537(0.145) 0.455(0.108) 0.092 Althea Medical Journal. 2015;2(1) Ester Mariska, Trully D. Sitorus, Januarsih A. Rachman: Effect of Centella asiatica Leaves on Gastric Ulcer in Rats 117 Table 2 Effect of Aspirin in Reducing Gastric Mucus Levels in Rats n Mean (SD) Mean Difference (CI 95%) P* Group I 6 0.112 (0.051) 0.077 (0.024-0.130) 0.006 Group II 6 (0.035 0.020) prevent declining of mucus levels of aspirin- Results induced gastric ulcer model in rats (p<0.05). Centella asiatica consists of triterpenoids The results of measurement of rat gastric common component in Centella asiatica.4 and flavonoids. Triterpenoid is the most mucus levels can be seen in Table 1. et al. There was a significant difference in the Centella asiatica has been proved to have induction of aspirin (450 mg/kg) can decrease rolesstated asthat wound asiaticoside healing, derived anti-inflammatory, from Centella mean of mucus level of gastric between asiatica groupmucus I leveland IIand (Table create 2). Thisa gastric result ulcer states model that and antioxidant. A research of Shukla in rats. had a role in wound healing in vitro and in vivo. It was proved by increasing tensile strength, collagen, fibroblast
Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0013741 A1 Meisel Et Al
    US 20040013741A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0013741 A1 Meisel et al. (43) Pub. Date: Jan. 22, 2004 (54) GASTROINTESTINAL COMPOSITIONS Publication Classification (51) Int. Cl." ......................... A61K 38/39; A61K 35/78; (76) Inventors: Gerard M. Meisel, Budd Lake, NJ A61K 33/06; A61K 33/08; (US); Arthur A. Ciociola, Far Hills, NJ A61K 31/12: A01N 33/02 (US) (52) U.S. Cl. ......................... 424/601; 424/692; 424/697; 424/731; 424/738; 424/750; 514/57; 514/23: 514/574; 514/540; Correspondence Address: 514/357; 514/651; 514/547; Warner-Lambert Company 514/680; 514/161; 514/282; 201 Tabor Road 514/2; 514/762 Morris Plains, NJ 07950 (US) (57) ABSTRACT The invention relates to compositions and methods for (21) Appl. No.: 10/196,053 treating and/or preventing lower gastrointestinal (GI) disor ders in mammalian patients, more particularly for alleviating and/or preventing the lower GI symptoms associated with (22) Filed: Jul. 15, 2002 Such disorders. US 2004/0013741 A1 Jan. 22, 2004 GASTRONTESTINAL COMPOSITIONS antagonists, Serotonin (5HT) receptor agonists, Selective 0001. This Continuation-In-Part application claims pri Serotonin reuptake inhibitor and mixtures thereof. ority to the utility application filed on Jul. 10, 2002 by SUMMARY OF THE INVENTION Express Mail No. EL819323530US. 0011. The present invention relates to compositions for FIELD OF THE INVENTION treating or preventing gastrointestinal disorders, comprising: 0002 The invention relates to compositions and methods 0012 a.) an amino-ether and/or -ester oxide having for treating and/or preventing lower gastrointestinal (GI) the formula: disorders in mammalian patients, more particularly for alle viating and/or preventing the lower GI symptoms associated with Such disorders.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al
    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Atc Index 2010
    ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine
    [Show full text]
  • ATC Klasifikators Ar Superscript Fontiem.Xls
    Kods Nosaukums A Gastrointestinālais trakts un vielmaiņa A01 Līdzekļi mutes dobuma un zobu slimību ārstēšanai A01A Līdzekļi mutes dobuma un zobu slimību ārstēšanai A01AA Līdzekļi kariesa profilaksei A01AA01 Natrii fluoridum A01AA02 Sodium monofluorophosphate A01AA03 Olaflur A01AA04 Stannous fluoride A01AA30 Combinations A01AA51 Sodium fluoride, combinations A01AB Pretinfekcijas un antiseptiskie līdzekļi mutes dobuma slimību vietējai ārstēšanai A01AB02 Hydrogen peroxide A01AB03 Chlorhexidinum A01AB04 Amphotericin b A01AB05 Polynoxylin A01AB06 Domiphen A01AB07 Oxyquinoline A01AB08 Neomycinum A01AB09 Miconazolum A01AB10 Natamycin A01AB11 Dažādi A01AB12 Hexetidinum A01AB13 Tetracycline A01AB14 Benzoxonium chloride A01AB15 Tibezonium iodide A01AB16 Mepartricin A01AB17 Metronidazolum A01AB18 Clotrimazolum A01AB19 Sodium perborate A01AB21 Chlortetracycline A01AB22 Doxycycline A01AB23 Minocycline A01AC Corticosteroids for local oral treatment A01AC01 Triamcinolone A01AC02 Dexamethasone A01AC03 Hydrocortisone A01AC54 Prednisolone, combinations A01AD Citi līdzekļi mutes dobuma slimību vietējai ārstēšanai A01AD01 Epinephrine A01AD02 Benzydamine A01AD05 Acetylsalicylic acid A01AD06 Adrenalone A01AD07 Amlexanox A01AD08 Becaplermin A01AD11 Dažādi A02 Zāles skābes izdales radītu traucējumu ārstēšanai A02A Antacīdi līdzekļi A02AA Magnija savienojumi A02AA01 Magnesium carbonate A02AA02 Magnesium oxide A02AA03 Magnesium peroxide A02AA04 Magnesium hydroxide A02AA05 Magnesium silicate A02AA10 Kombinācijas A02AB Alumīnija savienojumi A02AB01 Aluminium hydroxide
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2018 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]